LG Chem’s biosimilar etanercept, LBEC0101, referencing Enbrel, recently gained approval in Japan and the Republic of Korea. Among the data that led to its authorization were those deriving from a phase 3 study that demonstrated the biosimilar had equivalent efficacy and a comparable safety profile to the reference product. Recently, researchers reported on a single-arm, open-label extension study in patients with rheumatoid arthritis (RA) who completed the 52-week phase 3 study.
LG Chem’s biosimilar etanercept, LBEC0101, referencing Enbrel, recently gained approval in Japan and the Republic of Korea. Among the data that led to its authorization were those deriving from a phase 3 study that demonstrated the biosimilar had equivalent efficacy and a comparable safety profile to the reference product. Recently, researchers reported on a single-arm, open-label extension study in patients with rheumatoid arthritis (RA) who completed the 52-week phase 3 study.
A total of 148 patients entered the extension; 70 had been treated with the biosimilar and continued to receive the biosimilar as maintenance. The remaining 78 patients, all of whom had been treated with the reference etanercept, switched to the biosimilar. The patients, who self-administered 50 mg of the biosimilar and received concomitant methotrexate at a stable dose, were assessed up to week 100. Safety was evaluated up to week 102.
In both the biosimilar-only and the switch group, improvements in Disease Activity Score in a count of 28 joints (DAS28) that were observed in the phase 3 trial were maintained in the extension phase. At week 100, the least squares mean changes from week 52 in DAS28 with erythrocyte sedimentation rate were −0.052 (95% CI, −0.314 to 0.210) in the maintenance group and −0.149 (95% CI, −0.417 to 0.119) in the switch group. The estimated treatment difference between groups was 0.097 (95% CI, −0.200 to 0.393).
Response rates by American College of Rheumatology criteria and European League Against Rheumatism criteria were also similar between groups.
In the 52-week study, 90% and 89.7% of patients in the biosimilar-only and switch groups, respectively, reported adverse events (AEs). During the extension, 70.0% and 70.5%, respectively, reported AEs. The most commonly reported AEs were upper respiratory tract infection, nasopharyngitis, and arthralgia. Most AAEs were mild in severity.
In the present study, in the switch group, 5 patients reported a total of 10 injection-site reactions. One patient in the biosimilar-only group reported such a reaction.
During the extension, 1 patient in the biosimilar-only group and 1 patient in the switch group developed new anti-drug antibodies. No patients had neutralizing antibodies.
These results, write the authors, confirm that efficacy previously demonstrated for the biosimilar, both in patients who received maintenance therapy and in those who switched from the reference. The biosimilar was well tolerated, and no new safety concerns were identified.
Reference
Park MC, Matsuno H, Kim J, et al. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther. 2019;21(1):122. doi: 10.1186/s13075-019-1910-2.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.